SCHEMBL2406339

SCHEMBL2406339

Cc1cc(C(=O)NC(c2ccc(C(=O)NO)cc2)C(C)C)c(C)o1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.58
MAPT P10636 2/20 0.53
ALDH1A1 P00352 2/20 0.53
PKM P14618 1/20 0.53
HTT P42858 1/20 0.53
HSD17B10 Q99714 1/20 0.53
CYP26A1 O43174 6/20 0.51
HDAC6 Q9UBN7 3/20 0.48
HDAC8 Q9BY41 2/20 0.48
KDM4E B2RXH2 1/20 0.44
RAB9A P51151 2/20 0.44
HPGD P15428 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
NPC1 O15118 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HDAC3 O15379 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2408314 0.84 MAPT (0.49) HDAC1MAPTALDH1A1PKMHTT
SCHEMBL2407612 0.77 HDAC1 (0.60) HDAC1ALDH1A1HDAC6HDAC8HDAC3
SCHEMBL2408261 0.77 ALDH1A1 (0.58) MAPTALDH1A1PKMHTTHSD17B10
SCHEMBL2408190 0.76 HDAC1 (0.91) HDAC1ALDH1A1HSD17B10HDAC6HDAC8
SCHEMBL2408392 0.75 HDAC1 (0.58) HDAC1MAPTALDH1A1HSD17B10HDAC6
SCHEMBL12279611 0.75 HDAC1 (0.54) HDAC1ALDH1A1HDAC6HDAC8NPSR1
SCHEMBL2408207 0.74 HDAC1 (0.73) HDAC1ALDH1A1HTTHDAC6HDAC8
SCHEMBL14880163 0.74 MAPT (0.69) MAPTALDH1A1HSD17B10KDM4ERAB9A
SCHEMBL13753463 0.73 MAPT (0.59) MAPTALDH1A1PKMHTTHSD17B10
SCHEMBL2405287 0.73 HDAC1 (0.71) HDAC1ALDH1A1HTTHDAC6HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9382197-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-05 US disclosed
US-9382197-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-05 US disclosed
US-9382197-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-05 US disclosed
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-09-18 US disclosed
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-09-18 US disclosed
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-09-18 US disclosed
WO-2011106632-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 WO disclosed
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed
WO-2011106632-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 WO disclosed
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC10, HDAC1 HDAC1 3/4885MAPT 2484/4885ALDH1A1 1696/4885
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC10, HDAC1 HDAC1 3/4885MAPT 2484/4885ALDH1A1 1696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.